Introduction {#sec1-1}
============

Valproic acid (VA) is a branched and short-chain fatty acid, which is wide spreadly used for the epilepsy, migraine, and mental problems.\[[@ref1]\] Long-term VA treatment causes the increase of insulin and leptin levels resulting in hypercholesterolemia.\[[@ref2]\]

Hypercholesterolemia is a risk factor for atherosclerosis.\[[@ref3]\] The total cholesterol multiply the risk of coronary heart disease by 2.52--3.20 in productive ages.\[[@ref4]\] Several studies also depicted that there is an elevation of mortality by atherosclerosis in people with epilepsy.\[[@ref5]\]

The impact of VA on the level of total cholesterol is still in debate. Some studies demonstrated that there is a significant arrangement in cholesterol profiles, while others shown no impact of VA on cholesterol profiles.\[[@ref3]\] Regarding these controversies, we report the relationship of the long-term VA treatment and the level of total cholesterol among adult.

Materials and Methods {#sec1-2}
=====================

A Case-control study was performed among adult using VA for at least 1 month in the outpatient clinic Department of Neurology Dr. Soetomo Hospital Surabaya Indonesia period July-October 2018, with inclusion criteria: 18 years of age or more, and exclusion criteria: taking phenytoin and or carbamazepine, lipid-lowering drugs/statins and or gemfibrozil, and have a history of dyslipidemia before using VA accessed from interview and confirmed from medical record.

Sixty (30 case groups, level of total cholesterol more than 200mg/dL and 30 control groups, level of total cholesterol 200mg/dL or less) subjects were obtained by consecutive admission sampling method, then asked for fasting at least 8 hours for venous blood collection for the level of total cholesterol examination.

The level of total cholesterol was examined in using the Cholesterol CHOD-PAP Method kit (Biolabo SAS, France) and sample preparation were performed according to insert kit from the manufacturer.

Data were analyzed as follow: categorical scale data such as sex, body mass index (BMI) category, history of smoking, other drug use, diabetes mellitus, and anti epileptic drugs combination were cross-tabulated using the Chi-square test, while for numerical scale data such as age, weight and height of body, BMI, and a daily dose of VA were analyzed using two-independent sample *t*-test because their data were normally distributed. The relationship of the long-term VA treatment and the level of total cholesterol was obtained from the analysis using the Chi-square test then continued with logistic regression.

This study was approved by The Local Research Ethics Committee with ethical clearance certificate number 0347/KEPK /VI/2018.

Results {#sec1-3}
=======

The analysis of cross-tabulation for the confounding variables demonstrated that there were no significant association for sex, age, body height, body weight, BMI, history of other medication, diabetes mellitus, smoking and dose of VA, except the anti-epileptic drugs combination \[[Table 1](#T1){ref-type="table"}\].

###### 

Demographic characteristics of the participants (*n*=60), 30 cases (high total cholesterol) and 30 control (normal total cholesterol)

  Variables                                 Total cholesterol levels, mean±SD, *n* (%)   *P*           OR (95% CI)   
  ----------------------------------------- -------------------------------------------- ------------- ------------- ----------------------
  Gender                                                                                                             
   Men                                      15 (50)                                      11 (36.7)     0.297         1.727 (0.616-4.845)
   Women                                    15 (50)                                      19 (63.3)                   
  Age (year old)                            44.40±10.71                                  37.97±16.76   0.083         
  Body weight (kg)                          62.23±12.23                                  59.37±10.17   0.328         
  Body height (cm)                          159.73±7.61                                  159.57±8.55   0.937         
  BMI (kg/m^2^)                             24.35±4.36                                   23.34±3.79    0.341         
  Category of BMI                                                                                                    
   Overweight                               11 (36.7)                                    11 (36.7)     1.000         1.000 (0.350-2.858)
   Normal                                   19 (63.3)                                    19 (63.3)                   
  History of other medication                                                                                        
   Yes                                      6 (20)                                       1 (3.3)       0.103         7.250 (0.815-64.457)
   No                                       24 (80)                                      28 (96.7)                   
  Diabetes mellitus                                                                                                  
   Yes                                      5 (16.7)                                     2 (6.7)       0.424         2.800 (0.498-15.734)
   No                                       25 (83.3)                                    28 (93.3)                   
  Smoking                                                                                                            
   Yes                                      4 (13.3)                                     2 (6.7)       0.671         2.154 (0.363-12.764)
   No                                       26 (86.7)                                    28 (93.3)                   
  Antiepileptic drugs combination                                                                                    
   Yes                                      1 (3.3)                                      8 (26.7)      0.026\*       0.095 (0.011-0.815)
   No                                       29 (96.7)                                    22 (73.3)                   
  Daily dosage of valproic acid (mg/KgBW)   12.39±6.90                                   12.42±6.23    0.569         

\**P*\<0.05. BMI=Body mass index, OR=Odds ratio, CI=Confidence interval, SD=Standard deviation, mg/KgBW=Miligrams/Kilogram body weight

At present, there is no study that shows a cutoff point of time-related to the association of the time of VA treatment and the level of total cholesterol, herewith we use cutoff points of time of 12 months, obtained from the Receiver Operating Characteristic (ROC) curve.

The magnitude of the effect of the long-term VA treatment in the level of total cholesterol is presented in [Table 2](#T2){ref-type="table"}. The result showed that there was a relationship between the long term VA treatment at the 12-month cutoff points with the level of total cholesterol (*p* = 0.020, OR 0.289, 95% CI 0.100-0.837).

###### 

Association between duration of valproic acid treatment and serum total cholesterol levels

                                                 Total cholesterol levels, *n* (%)   *P*         OR (95% CI)   
  ---------------------------------------------- ----------------------------------- ----------- ------------- ---------------
  Duration of valproic acid treatment (months)                                                                 
   \>12                                          10 (33.3)                           19 (63.3)   0.020\*       0.289
   \<12                                          20 (66.7)                           11 (36.7)                 (0.100-0.837)
   Total                                         30 (100)                            30 (100)                  

\**P*\<0.05. OR=Odds ratio, CI=Confidence interval

Data analysis was then continued using logistic regression for the variable time of VA treatment, anti-epileptic drugs combination, and the level of total cholesterol. The result of the analysis still demonstrated that there was an association between the time of VA treatment and the level of total cholesterol (*p* = 0.024, adjusted OR 0.272 with 95% CI 0.088-0.844 for the long term use of VA), this means that the use of VA for more than 12 months has a risk of 3.68 times smaller than the use of 12 months or less to have a high level of total cholesterol \[[Table 3](#T3){ref-type="table"}\].

###### 

Multivariate analysis association between duration of valproic acid treatment, combination of antiepileptic drugs, and serum total cholesterol levels

                                        *P*       Adjusted OR   95% CI
  ------------------------------------- --------- ------------- -------------
  Duration of valproic acid treatment   0.024\*   0.272         0.088-0.844
  Combination of antiepileptic drugs    0.031\*   0.088         0.010-0.799

\**P*\<0.05. OR=Odds ratio, CI=Confidence interval

Discussion {#sec1-4}
==========

The relationship of long-term VA treatment and the level of total cholesterol in this study was seen at the cut-off point of 12 months. At the cut-off point of 12 months use of VA, it was found that there was a significant relationship between the time of VA treatment and the level of total cholesterol, where people who used VA for more than 12 months had a risk of 3.68 times smaller to have high serum total cholesterol levels compared to people who used VA 12 months or less.

Our results are similar to those of Nisha *et al*., 2018 that compared the level of total cholesterol in a newly diagnosed group of epilepsy and epilepsy patients who were treated with VA for more than 12 months. The study proves that the level of total cholesterol in the group of VA was lower than the group of the newly diagnosed group.\[[@ref6]\]

The result of our study is also similar to those of Kantoush *et al*., which showed that the level of total cholesterol, triglycerides, and other cholesterols in children with epilepsy given VA was lower than in the control group.\[[@ref7]\] In addition, Abidemi *et al*., using alloxan-induced Wistar rats showed that VA significantly reduced triglyceride, total cholesterol, and LDL cholesterol levels.\[[@ref8]\]

The result of our study is also similar to those of Kantoush *et al*., which showed that the level of total cholesterol, triglycerides, and other cholesterols in children with epilepsy given VA was lower than in the control group.\[[@ref7]\] In addition, Abidemi *et al*., using alloxan-induced Wistar rats showed that VA significantly reduced triglyceride, total cholesterol, and LDL cholesterol levels.\[[@ref8]\]

The result of this study showed that people who used VA for more than 12 months had a risk of having a high level of total cholesterol, 3.68 times less than those who used VA 12 months or less. This shows that the use of VA for more than 12 months decreases the level of total cholesterol. In another word, might be there is the potency of long term use of VA for the decrease or improvement the lipid profiles especially total cholesterol. Decreasing total cholesterol levels in the use of long-term VA can be caused by improvements in some organs/organelles which also contribute to cholesterol metabolism. Huang *et al*., 2017 showed that VA inhibits oxidative stress in the endoplasmic reticulum via the pathway of glycogen synthase kinase 3/β which contributes to cholesterol metabolism and the pathogenesis of atherosclerosis.\[[@ref9]\]

In addition, it is hypothesized that VA enhances the proliferation, differentiation, and function of pancreatic beta cells after pancreatitis, thereby improving the process of insulin secretion through an inhibitory mechanism in histone deacetylase (HDAC).\[[@ref10]\] HDAC is a protein that contributes in the recovery process of pancreatic beta cell damage, thereby improving the insulin secretion process.\[[@ref11]\]

Conclusion {#sec1-5}
==========

The use of VA for more than 12 months decreases the level of total cholesterol.
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